From Infection to Tumor: Exploring the Therapeutic Potential of Ciprofloxacin Derivatives as Anticancer Agents.

IF 5.7 3区医学 Q2 CHEMISTRY, MEDICINAL

Pharmaceuticals Pub Date : 2025-01-09 DOI:10.3390/ph18010072

Hesham M Hassan, Roket Hassan, Ranya Mohammed Elmagzoub, Ahmed Al-Emam, Konstantinos Kossenas, Ahmed S Abdel-Samea, Hazim O Khalifa, Suleyman Akocak, Stefan Bräse, Hamada Hashem

{"title":"From Infection to Tumor: Exploring the Therapeutic Potential of Ciprofloxacin Derivatives as Anticancer Agents.","authors":"Hesham M Hassan, Roket Hassan, Ranya Mohammed Elmagzoub, Ahmed Al-Emam, Konstantinos Kossenas, Ahmed S Abdel-Samea, Hazim O Khalifa, Suleyman Akocak, Stefan Bräse, Hamada Hashem","doi":"10.3390/ph18010072","DOIUrl":null,"url":null,"abstract":"<p><p>Ciprofloxacin, a widely used second-generation fluoroquinolone for treating bacterial infections, has recently shown notable anticancer properties. This review explores progress in developing ciprofloxacin derivatives with anticancer properties, emphasizing key structural changes that improve their therapeutic effectiveness by modifying the basic group at position 7, the carboxylic acid group at position 3, or both. It further investigates the mechanisms by which these derivatives fight cancer, such as inducing apoptosis, arresting the cell cycle, inhibiting topoisomerase I and II, preventing tubulin polymerization, suppressing interleukin 6, blocking thymidine phosphorylase, inhibiting multidrug resistance proteins, and hindering angiogenesis. Additionally, it outlines their future directions, such as enhancing their efficacy, selectivity, and investigating potential synergy with other chemotherapeutic agents, offering a promising avenue for developing new therapies for cancer.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 1","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11768150/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18010072","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Ciprofloxacin, a widely used second-generation fluoroquinolone for treating bacterial infections, has recently shown notable anticancer properties. This review explores progress in developing ciprofloxacin derivatives with anticancer properties, emphasizing key structural changes that improve their therapeutic effectiveness by modifying the basic group at position 7, the carboxylic acid group at position 3, or both. It further investigates the mechanisms by which these derivatives fight cancer, such as inducing apoptosis, arresting the cell cycle, inhibiting topoisomerase I and II, preventing tubulin polymerization, suppressing interleukin 6, blocking thymidine phosphorylase, inhibiting multidrug resistance proteins, and hindering angiogenesis. Additionally, it outlines their future directions, such as enhancing their efficacy, selectivity, and investigating potential synergy with other chemotherapeutic agents, offering a promising avenue for developing new therapies for cancer.

Abstract Image

查看原文本刊更多论文

从感染到肿瘤：探索环丙沙星衍生物作为抗癌药物的治疗潜力。

环丙沙星是一种广泛用于治疗细菌感染的第二代氟喹诺酮类药物，最近显示出显著的抗癌特性。本文综述了具有抗癌特性的环丙沙星衍生物的开发进展，强调了通过改变7位基或3位羧基或两者同时改变来提高其治疗效果的关键结构变化。它进一步研究了这些衍生物的抗癌机制，如诱导细胞凋亡，阻滞细胞周期，抑制拓扑异构酶I和II，阻止微管蛋白聚合，抑制白细胞介素6，阻断胸苷磷酸化酶，抑制多药耐药蛋白和阻碍血管生成。此外，它还概述了它们未来的发展方向，如提高它们的疗效、选择性和研究与其他化疗药物的潜在协同作用，为开发新的癌症治疗方法提供了一条有希望的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

6.10

自引率

4.30%

发文量

1332

审稿时长

6 weeks

期刊介绍： Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.